R&D channel feed

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

6 months ago
Pharma

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

6 months ago
Pharma

Is there room for MASH drugs in a GLP-1 world?

6 months ago
Pharma
In Focus

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

6 months ago
Pharma

Cin­Rx touts pos­i­tive ear­ly-stage da­ta from two obe­si­ty can­di­dates

6 months ago

No­vo Nordisk claims late-stage MASH vic­to­ry, con­tin­u­ing GLP-1's ex­pan­sion

6 months ago

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

6 months ago

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

6 months ago

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

6 months ago
Pharma

Take­da says mul­ti­year re­struc­tur­ing is 'on track'

6 months ago
Pharma

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

6 months ago

Cor­cept miss­es pri­ma­ry end­point in sup­port­ive Cush­ing's syn­drome study

6 months ago

Com­pass Path­ways de­lays key Phase 3 psilo­cy­bin read­outs, spurring 30% lay­offs

6 months ago

Lex­eo shares ear­ly da­ta on Alzheimer’s gene ther­a­py 

6 months ago

Roche presents ear­ly-stage re­sults for lat­est amy­loid-based Alzheimer's at­tempt

6 months ago

At­las of tu­mors re­veals in 3D how cells change in­to can­cer

6 months ago
Discovery
Diagnostics

Hints of im­pa­tience grow with Bio­gen as it tries to find a bridge to growth

6 months ago
Pharma

GSK cuts 24-va­lent pneu­mo­coc­cal pro­gram for adults due to com­pe­ti­tion

6 months ago

Bio­gen signs mol­e­c­u­lar glue deal, rais­es year­ly pro­jec­tions

6 months ago
Deals
Pharma

Sage, Bio­gen won't pur­sue ma­jor de­pres­sion ap­proval for post­par­tum pill

6 months ago

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

6 months ago
Pharma

Coya shares sink on Phase 2 Alzheimer's da­ta for de­pri­or­i­tized drug

6 months ago

Sh­iono­gi touts topline da­ta for Covid-19 an­tivi­ral for post-ex­po­sure treat­ment

6 months ago
Pharma

PacBio bets on 'in­flec­tion point' with $500 long-read genome

7 months ago
Diagnostics
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times